News

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have gained 15.4% in a year against the industry’s decline of 10.8%. The stock has outperformed the sector but lagged the S&P 500 Index.

Approval of new drugs, encouraging pipeline progress, positive data readouts and strong quarterly results have boosted investors’ sentiment in the past six months. GILD has also raised its annual guidance for sales and earnings, driven by growth in COVID-19 treatment Veklury sales.

Gilead Outperforms Industry & Sector

Image Source: Zacks Investment Research

GILD’s Leading HIV Franchise Maintains Momentum

Gilead has a market-leading portfolio of HIV treatments, and the company’s efforts to develop additional innovative HIV treatments are being appreciated by investors.

With a market share of more than 49% in the United States at the end of the third quarter, its flagship HIV therapy, Biktarvy, continues to fuel the top line. The strong momentum in Biktarvy has enabled Gilead to increase its HIV sales target to 5% in 2024 from the earlier estimate of 4%.

Gilead’s efforts to innovate its HIV portfolio are impressive. The company’s pipeline candidate, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option.

Gilead expects to file for approval of lenacapavir for HIV prevention before the end of the year. The successful development and potential approval of lenacapavir for PrEP should solidify Gilead’s HIV franchise, as lenacapavir needs to be taken twice yearly, unlike daily oral pills.

Approval of Additional Drugs Strengthens GILD’s Portfolio

In August 2024, the FDA accelerated approval of seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA.

The candidate was approved under the brand name Livdelzi. In March 2024, GILD acquired CymaBay Therapeutics Inc. for $4.3 billion, adding Seladelpar to its portfolio/pipeline. Livdelzi's approval strengthens GILD’s liver disease portfolio and validates its CymaBay acquisition.

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recently gave a positive opinion recommending approval of seladelpar for the treatment of PBC in the EU. A final decision is anticipated in the first quarter of 2025.

Gilead Sciences recently entered into a multi-target research collaboration with Terray Therapeutics to discover and develop novel small-molecule therapies for multiple targets.

GILD’s Oncology Franchise Faces Challenges

Gilead’s oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified the company’s overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds, which are expected to continue in 2025.

Breast cancer drug Trodelvy has performed well since its approval. However, Gilead’s efforts to expand Trodelvy’s label suffered a setback due to the failure of its late-stage confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer. In January, the late-stage study evaluating Trodelvy in previously treated metastatic non-small cell lung cancer also failed. These failures have somewhat dented Gilead’s efforts to strengthen its oncology franchise.

Nonetheless, the FDA recently granted Breakthrough Therapy Designation to Trodelvy for the treatment of adult patients with extensive-stage small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy.

Valuation & Estimates

According to the price/earnings ratio, GILD’s shares currently trade at 12.22x forward earnings, lower than the large-cap pharma industry average of 16.17 but higher than its mean of 10.35.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for its 2024 earnings per share (EPS) has moved up 59 cents to $4.36 over the past 60 days. It’s worth noting that the annual earnings estimates have taken a hit due to acquisition-related expenses in 2024.The EPS for 2025 has also gained 28 cents during the same time frame.

Image Source: Zacks Investment Research

Conclusion

Gilead’s efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The company’s strategic deals and acquisitions to diversify its business are encouraging.

GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Recently reported data showed that a treatment switch to an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression in adults at week 48. Islatravir is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation in multiple ongoing early and late-stage clinical studies in combination with other antiretrovirals for the treatment of HIV-1.

Gilead’s strong fundamentals make it a good biotech stock to buy and hold for the long term. At current levels, we believe there is more room for growth.

The company’s attractive dividend yield is another positive. Gilead has been consistently increasing and paying out dividends. Its strong cash position (as of Sept. 30, 2024, GILD had $5 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 3.38% is likely to be sustainable.

Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Names #1 Semiconductor Stock

It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.

With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.

See This Stock Now for Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report

GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report

Merck & Co., Inc. (MRK) : Free Stock Analysis Report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.